{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:47:36Z","timestamp":1792478856769,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejps.2023.106578","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:58:25Z","timestamp":1693789105000},"page":"106578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects"],"prefix":"10.1016","volume":"190","author":[{"given":"Sufeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-7299","authenticated-orcid":false,"given":"Feng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2023.106578_bib0001","series-title":"Proton Pump Inhibitors (PPI)","author":"Ahmed","year":"2022"},{"key":"10.1016\/j.ejps.2023.106578_bib0002","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1111\/jgh.15700","article-title":"Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori","volume":"36","author":"Bunchorntavakul","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2023.106578_bib0003","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/apt.16959","article-title":"The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study","volume":"55","author":"Chen","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106578_bib0005","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/apt.15438","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"50","author":"Han","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0006","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.clinthera.2021.06.007","article-title":"Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan","volume":"43","author":"Han","year":"2021","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0007","doi-asserted-by":"crossref","DOI":"10.7326\/L15-5181","article-title":"In the clinic. gastroesophageal reflux disease","volume":"163","author":"Harnik","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejps.2023.106578_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40261-020-00986-4","article-title":"Safety, tolerability and pharmacokinetics of single ascending and multiple oral doses of tegoprazan in healthy Chinese subjects","volume":"41","author":"He","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejps.2023.106578_bib0009","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2023.106578_bib0011","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.amjmed.2018.12.009","article-title":"Diagnosis and treatment of peptic ulcer disease","volume":"132","author":"Kavitt","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejps.2023.106578_bib0012","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12876-021-01822-5","article-title":"Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial","volume":"21","author":"Kawai","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ejps.2023.106578_bib0013","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.pop.2017.07.001","article-title":"Gastroesophageal reflux disease","volume":"44","author":"Kellerman","year":"2017","journal-title":"Prim. Care"},{"key":"10.1016\/j.ejps.2023.106578_bib0014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5056\/jnm18001","article-title":"Advantages and disadvantages of long-term proton pump inhibitor use","volume":"24","author":"Kinoshita","year":"2018","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.ejps.2023.106578_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial","volume":"164","author":"Laine","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2023.106578_bib0016","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","article-title":"Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects","volume":"117","author":"Laine","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2023.106578_bib0017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(16)32404-7","article-title":"Peptic ulcer disease","volume":"390","author":"Lanas","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2023.106578_bib0018","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2017.06.020","article-title":"KFP-H008 blocks gastric acid secretion through inhibiting H(+)-K(+)-ATPase","volume":"810","author":"Li","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106578_bib0019","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cpdd.1009","article-title":"The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan","volume":"11","author":"Mulford","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejps.2023.106578_bib0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.ejps.2023.106578_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/nyas.14428","article-title":"Potential proton pump inhibitor-related adverse effects","volume":"1481","author":"Perry","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejps.2023.106578_bib0022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J. Gastrointest Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0023","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","article-title":"Presentation and epidemiology of gastroesophageal reflux disease","volume":"154","author":"Richter","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2023.106578_bib0024","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects\u2013a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/nyas.14473","article-title":"Pharmacologic treatment of GERD: where we are now, and where are we going?","volume":"1482","author":"Scarpignato","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejps.2023.106578_bib0026","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/apt.16121","article-title":"Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects","volume":"52","author":"Sunwoo","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0027","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/apt.14818","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects","volume":"48","author":"Sunwoo","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0028","doi-asserted-by":"crossref","first-page":"l5495","DOI":"10.1136\/bmj.l5495","article-title":"Peptic ulcer disease","volume":"367","author":"Sverden","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejps.2023.106578_bib0029","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apt.15641","article-title":"Randomised trial of acid inhibition by vonoprazan 10\/20mg once daily vs rabeprazole 10\/20mg twice daily in healthy Japanese volunteers (SAMURAI pH study)","volume":"51","author":"Takeuchi","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106578_bib0030","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/jgh.16000","article-title":"Efficacy of keverprazan for duodenal ulcer: a phase II randomized, double-blind, parallel-controlled trial","volume":"37","author":"Tan","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2023.106578_bib0031","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.3748\/wjg.14.6334","article-title":"Ghrelin and gastric acid secretion","volume":"14","author":"Yakabi","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2023.106578_bib0032","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1111\/bcp.15268","article-title":"Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole","volume":"88","author":"Yang","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106578_bib0033","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/cts.12958","article-title":"Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers","volume":"14","author":"Yoon","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejps.2023.106578_bib0034","first-page":"S","article-title":"W1100 intragastric pH holding time of pH< 4 predicts low erosive esophagitis (EE) healing rate","volume":"5","author":"Yuan","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2023.106578_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13598","article-title":"Keverprazan, a novel potassium-competitive acid blocker Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects","author":"Zhou","year":"2023","journal-title":"Clin. Transl. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723002087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723002087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:09:48Z","timestamp":1760530188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723002087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"alternative-id":["S0928098723002087"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106578","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106578"}}